Here are 1-2 brief analogies for Actinium Pharmaceuticals (ATNM):

• Like Seagen (known for antibody-drug conjugates), but they use radioactive isotopes as the targeted payload instead of chemotherapy drugs for precision cancer therapy.
• Like Novartis's Pluvicto, but specializing in using targeted radiation to prepare patients for bone marrow transplants and other advanced cell therapies.

• I-131 apamistamab (Iomab-B): A lead product candidate, currently in a pivotal Phase III clinical trial, designed as a radiolabeled antibody for bone marrow transplant conditioning in elderly relapsed or refractory acute myeloid leukemia.
• Radiopharmaceutical Therapies Pipeline: A comprehensive pipeline of clinical and preclinical programs utilizing various radioisotopes (including Actinium-225, Iodine-131, and Lutetium-177) to develop targeted conditioning therapies for cell and gene therapies, as well as cancer therapeutics as single agents or in combination.

Actinium Pharmaceuticals, Inc. (ATNM) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies. As such, the company does not currently have major commercial customers purchasing approved products or services.

Its primary activities at this stage involve:

• Research and Development: Advancing product candidates through preclinical and clinical trials. For example, its lead product candidate, I-131 apamistamab (Iomab-B), is in a pivotal Phase III clinical trial.
• Strategic Collaborations: Engaging in partnerships for the development of new therapies and theranostics. The company has collaborations with:
  • Astellas Pharma, Inc. (TYO: 4503)
  • EpicentRx, Inc. (a private company)
  • AVEO Oncology (now part of LG Chem, no longer publicly traded under AVEO)
  These relationships are for shared development, potential future commercialization rights, or research activities, and are not traditional customer relationships involving the sale of current products.
• Clinical Trial Partnerships: Working with medical institutions, such as Memorial Sloan Kettering Cancer Center, to conduct clinical studies. These institutions are research partners rather than direct customers purchasing commercial products.

Therefore, Actinium Pharmaceuticals does not currently sell its products primarily to other companies or to individual customers. Upon successful regulatory approval and commercialization of its product candidates, its customers would typically include healthcare providers, hospitals, and potentially pharmaceutical distributors, rather than individual patients directly.

Sandesh Seth, Chief Executive Officer and Chairman

Sandesh Seth has over 25 years of experience across investment banking (Laidlaw& Co (UK) Ltd., Cowen & Co.), equity research (Bear Stearns, Commonwealth Associates), and the pharmaceutical industry (Pfizer, Warner-Lambert, SmithKline) in strategic planning, business development, and R&D project management. He co-founded and served as chairman of Relmada Therapeutics Inc., a specialty pharmaceutical company focused on CNS therapeutics. Mr. Seth holds an MBA in Finance from New York University, an M.S. in Pharmaceutical Sciences from the University of Oklahoma Health Center, and a B.Sc. in Chemistry from Bombay University.

Steve O'Loughlin, Chief Financial Officer

Steve O'Loughlin was appointed Chief Financial Officer in July 2020, having previously served as Principal Financial Officer since May 2017. He joined Actinium in October 2015 as Vice President, Finance and Corporate Development. Mr. O'Loughlin possesses nearly fifteen years of life sciences industry experience, including previous positions in investment banking at J. Streicher LLC and Jesup & Lamont, and corporate development roles at publicly traded life sciences companies such as Protea Biosciences, Inc. and Caliber I.D. (formerly Lucid, Inc.).

Dr. Avinash Desai, Chief Medical Officer

Dr. Avinash Desai is a hematologist/oncologist with nearly 25 years of experience in drug development. Throughout his career, Dr. Desai has successfully designed and implemented clinical development, U.S. and global medical affairs, and life cycle management plans for various pharmaceutical products, including participation in multiple INDs, NDAs, and sNDA submissions. He previously served as Vice President, Head of U.S. Medical Affairs – Oncology at GlaxoSmithKline (GSK), where he established the U.S. medical affairs oncology team and oversaw launch readiness plans for three novel oncology products. His prior roles include overseeing oncology life cycle management plans at Eli Lilly & Company, Janssen Pharmaceuticals, Inc., and Takeda, Inc. Dr. Desai contributed to the approval of Janssen's Darzalex® and led medical affairs activities globally for Velcade®. Earlier, at Sanofi, he successfully executed pivotal trials for oncology products, leading to NDA submission for Jevtana®.

Dr. Arun Swaminathan, Chief Business and Commercial Officer

Dr. Arun Swaminathan is an accomplished executive with over 20 years of experience in the global biopharmaceutical industry, spanning commercial, business development, and clinical roles. Prior to joining Actinium, he was the Chief Business Officer and Senior Vice President at Alteogen Inc., a South Korea-based biopharmaceutical company, where his negotiations led to deals totaling over $6 billion in potential value. During his tenure at Alteogen, the company's market value increased significantly. Dr. Swaminathan also co-founded and served as CEO of Lynkogen Inc., where he raised capital and advanced drug candidates from concept to pre-clinical stage.

Jenny Hsieh, Chief Strategy Officer

Jenny Hsieh joined Actinium as Chief Strategy Officer from Gilead Sciences, following its acquisition of Immunomedics. She holds a BA from the University of Pennsylvania, an MBA from NYU's Stern School of Business, and an MPA from NYU's Wagner Graduate School of Public Service.

1. Clinical Development and Regulatory Approval Risk

As a clinical-stage company with its lead product candidate, I-131 apamistamab (Iomab-B), in a pivotal Phase III clinical trial, Actinium Pharmaceuticals' success is highly dependent on achieving positive clinical trial results and obtaining regulatory approvals. The failure of Iomab-B or other pipeline candidates in any stage of clinical development would severely impact the company's prospects. Even if trials are successful, there are no guarantees of satisfying all regulatory requests or overcoming additional regulatory hurdles, which could lead to non-acceptance or non-approval of a Biologics License Application (BLA). The drug development process is lengthy, costly, and has a high attrition rate, with a significant percentage of compounds failing in various clinical stages.

2. Commercialization and Market Adoption Risk

Even if Actinium Pharmaceuticals' product candidates receive regulatory approval, there is a substantial risk that they may not achieve significant market acceptance or compete effectively against existing or future treatments in the bone marrow transplant and cellular therapy markets. Challenges include potential pricing pressures, securing favorable reimbursement policies, and establishing a strong market presence. For instance, Iomab-ACT, a targeted conditioning agent, faces competition from established non-targeted chemotherapy regimens. A product can receive approval but still achieve lackluster sales, underscoring the complexities of market adoption in the biopharmaceutical industry.

3. Funding and Financial Stability Risk

As a clinical-stage biopharmaceutical company, Actinium Pharmaceuticals is continuously reliant on securing adequate funding to advance its product candidates through extensive and costly development processes. The company is currently unprofitable and is not forecast to become profitable in the near future. The biotech industry, in general, faces challenges in raising capital, with investors becoming more selective. Delays in clinical trials or failures can exacerbate funding challenges, potentially leading to dilution of existing shareholders through equity offerings or hindering the ability to further develop its pipeline.

Actinium Pharmaceuticals, Inc. (ATNM) is a clinical-stage biopharmaceutical company with several potential drivers of future revenue growth over the next 2-3 years, primarily centered around its lead product candidate, Iomab-B, and its broader radiotherapeutic pipeline.

1. Commercialization of Iomab-B in European, Middle Eastern, and North African Markets: Actinium Pharmaceuticals has a strategic licensing and supply agreement with Immedica Pharma AB for the commercialization of Iomab-B in the European Economic Area, the Middle East, and North Africa (MENA) regions. This agreement, established in April 2022, includes an upfront payment and significant potential for an additional $417 million in regulatory and sales milestone payments, along with mid-twenty percent royalties upon approval in these territories. These ex-U.S. markets represent a substantial commercial opportunity for Iomab-B.
2. Potential Milestone Payments from Existing Collaborations: The company has ongoing collaborations with partners such as Astellas Pharma, Inc. for theranostics in solid tumor indications, EpicentRx, Inc. for a novel CD47 immunotherapy targeted radiotherapy, and AVEO Oncology for developing a HER3 targeting Antibody Radiation Conjugate (ARC) for solid tumors. Achieving specific developmental, regulatory, or sales milestones within these partnerships could trigger significant payments, contributing to revenue growth.
3. Advancement and Future Commercialization of Iomab-ACT for Cell and Gene Therapies: Actinium is developing Iomab-ACT, a next-generation CD45-targeted ARC, as a conditioning agent for cell and gene therapies. This includes an Investigational New Drug (IND) clearance from the FDA in July 2024 to study its use prior to bone marrow transplant (BMT) in sickle cell disease patients. Successful progression and potential commercialization of Iomab-ACT, especially its application with approved gene therapies like Casgevy and Lyfgenia, could open up a new revenue stream beyond the current focus on Acute Myeloid Leukemia (AML).

Share Issuance

• Actinium Pharmaceuticals entered into an Amended and Restated Capital on Demand™ Sales Agreement on June 28, 2022, allowing for the offering of common stock through sales agents.
• The company's common stock outstanding increased from 27,634,213 shares on January 1, 2024, to 30,550,602 shares by June 30, 2024, with additional paid-in capital increasing by approximately $27.5 million during the same period, indicating significant capital raised through share issuances.
• As of Q3 2025, Actinium Pharmaceuticals had 31 million shares outstanding.

Capital Expenditures

• Actinium Pharmaceuticals reported $0 in capital expenditures for Q3 2024 and Q3 2025.
• For the six months ended June 30, 2024, the company's purchase of property and equipment was ($11) thousand, and it was $0 for the six months ended June 30, 2025.
• The company announced plans in 2025 to establish radiopharmaceutical manufacturing infrastructure, including Actinium-225 cyclotron manufacturing technology, to support its expanding clinical pipeline.